Key Episode Timestamps 00:00:01 Introduction and Participant Backgrounds 00:01:18 Overview of MASH and Insulin Resistance 00:03:28 Phase 2 and Phase 3 Trials of Semaglutide 00:07:23 Significant Findings and Clinical Implications 00:09:44 Challenges and Future Directions 00:14:50 Mechanism of Action and Weight Loss 00:17:39 Data on Weight Loss and Liver Improvement 00:20:42 Potential for FDA Approval and Future Studies 00:25:04 Conclusion and Final Thoughts In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis

We also compared patients who suffered from obesity who had T2DM (~33%) and those who did not (~67%)
With Midi Health, you're getting a cut above care visits with legitimate doctor's specializing in perimenopause through post menopause
Never stop or adjust your medication without professional guidance
I knew it was worth trying this medication and adding it alongside a nutrition and personal training regimen that I had already started